Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- March 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- March 1, 2023 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- February 27, 2023 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
- February 22, 2023 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- February 22, 2023 Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- February 21, 2023 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
- February 17, 2023 FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
- February 13, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- January 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- January 5, 2023 Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
Displaying 11 - 20 of 235